Skip to content

Effect of date seed coffee extract on type 2 diabetic patients

Effect date seed (Phoenix dactylifera L) coffee extract on blood sugar control in type 2 diabetic patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20080901001157N22
Enrollment
80
Registered
2025-02-19
Start date
2025-04-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. E11

Interventions

Intervention 1: Intervention group: Patients in this group receive a 300 mg capsule of date seed coffee extract twice a day after food. The herbal drug capsule contains date seed coffee extract and wi

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with mild to moderate type 2 diabetes Age 40 to 60 years Have diabetes for at least two years Under treatment with or without anti-diabetic drugs Fasting blood glucose levels between 130 to 170 mg/dL Glycosylated hemoglobin between 7.5 to 8.5%

Exclusion criteria

Exclusion criteria: Patients with diabetic foot ulcer and gangrene Patients with any severe illness Patients with painful diabetic neuropathy Depressed patients Smokers or alcoholic patients Patients who tend to change their exercise program or diet

Design outcomes

Primary

MeasureTime frame
Glycosylated hemoglobin. Timepoint: At starting of the study and after 3 months. Method of measurement: Glycosylated hemoglobin will be determined in laboratory by commercial standard kit.;Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercial standard kit.

Secondary

MeasureTime frame
Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercially available kit.;Low-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood low-density lipoprotein level will be determined in laboratory by commercially available kit.;High-density lipoprotein. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood High-density lipoprotein level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood aspartate aminotransferase level will be determined in laboratory by commercially available kit.;Alanine aminotransferase. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood alanine aminotransferase level will be determined in laboratory by commercially available kit.;Blood urea nitrogen. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood blood urea nitrogen level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Fallah Huseini

Iranian academic center for education culture and research

h.fallah@acecr.ac.ir+98 26 3476 4010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026